Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Region Stockholm
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05679024CT.gov Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation | — | Recruiting | — | — | — |
NCT04878497CT.gov Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty | — | Unknown | — | — | — |
NCT04808934CT.gov NOAC Portuguese Real World Study | — | Withdrawn | — | — | — |
NCT03568916CT.gov Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hemorrhagic Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apixaban (this asset) | Region Stockholm | P3 | B · 60 |
| Damoctocog Alfa Pegol | Bayer | P4 | BBB |
| Rivaroxaban | Brigham and Women's Hospital | P4 | BBB |
| Warfarin | Asan Medical Center | P4 | BBB |
| Alteplase | Hamilton Health Sciences Corporation | P4 | BB |
| Pcc | University Health Network, Toronto | P4 | BB |
| Blood Plasma | University Health Network, Toronto | P4 | BB |
| Human Fibrinogen | University Health Network, Toronto | P4 | BB |
| bay94-9027 | Bayer | P3 | BB |
+16 more in the Hemorrhagic Disease cohort
Other indications for Apixaban
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Venous Thromboembolism | — | P4 | BBB · 79 |
| Atrial Fibrillation | — | P4 | BBB · 77 |
| Transient Ischemic Attack | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apixaban in Hemorrhagic Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/apixaban-hemorrhagic-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →